Title:
NOVEL FUSION PROTEIN AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/217288
Kind Code:
A1
Abstract:
Provided are modifications of human interleukin-2 (IL-2) and interferon α (IFNα), a fusion protein formed by modified IL-2, IFNα, or both of IL-2/IFNα and an Fc, and design, preparation and use of the fusion protein. By changing the binding capacity of IFNα to a receptor thereof by means of gene mutation, a superior fusion protein is acquired, which may overcome the defects of weak specificity and serious adverse effects of existing drugs.
Inventors:
LIU LIMING (CN)
HAN ZHEN (CN)
KANG PING (CN)
HAN ZHEN (CN)
KANG PING (CN)
Application Number:
PCT/CN2023/094205
Publication Date:
November 16, 2023
Filing Date:
May 15, 2023
Export Citation:
Assignee:
NANJING JSIAMA BIOPHARMACEUTICALS LTD (CN)
International Classes:
C07K19/00; A61K38/19; A61K38/20; A61K47/65; A61K47/68; A61P35/00; C12N15/85
Foreign References:
| CN114853909A | 2022-08-05 | |||
| CN112218884A | 2021-01-12 | |||
| TW202144391A | 2021-12-01 | |||
| CN112724259A | 2021-04-30 | |||
| CN101970492A | 2011-02-09 | |||
| CN108727504A | 2018-11-02 |
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF: